Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilovertamab vedotin plus R-CHP vs polatuzumab vedotin plus R-CHP in treatment-naive GCB diffuse large B-cell lymphoma
2024-515526-89-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of zilovertamab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Merck & Co. Primary endpoint: Complete Response Rate at End of Treatment. Planned start May 2025; status: authorised.
02
Drugs
zilovertamab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2024-515526-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515526-89-00.